etoposide has been researched along with zd 6474 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
DeRyckere, D; Gore, L; Macy, ME | 1 |
Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
1 trial(s) available for etoposide and zd 6474
Article | Year |
---|---|
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
4 other study(ies) available for etoposide and zd 6474
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia; Methotrexate; Piperidines; Protein Kinase Inhibitors; Quinazolines; Topoisomerase II Inhibitors | 2012 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |